Menu
Search
|

Menu

Close
X

Lupin Ltd LUPN.NS (National Stock Exchange of India)

763.00 INR
-7.90 (-1.02%)
As of 11:32 PM EST
chart
Previous Close 770.90
Open 776.00
Volume 357,194
3m Avg Volume 1,849,292
Today’s High 776.00
Today’s Low 761.30
52 Week High 986.10
52 Week Low 723.65
Shares Outstanding (mil) 452.45
Market Capitalization (mil) 350,537.00
Forward P/E --
Dividend (Yield %) 5.00 ( 0.65 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.31 Mean rating from 39 analysts

KEY STATS

Revenue (mm, INR)
FY19
123,119
FY18
158,308
FY17
174,943
FY16
142,555
EPS (INR)
FY19
6.968
FY18
5.497
FY17
56.467
FY16
49.898
*Note: Units in Millions of Rupee
**Note: Units in Rupee

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.99
Price to Sales (TTM)
vs sector
2.14
10.11
Price to Book (MRQ)
vs sector
--
4.60
Price to Cash Flow (TTM)
vs sector
56.67
26.60
Total Debt to Equity (MRQ)
vs sector
--
16.95
LT Debt to Equity (MRQ)
vs sector
--
13.45
Return on Investment (TTM)
vs sector
--
12.72
Return on Equity (TTM)
vs sector
--
13.73

EXECUTIVE LEADERSHIP

Manju Gupta
Chairman of the Board, Since 2017
Salary: Rs4,570,000.00
Bonus: --
Vinita Gupta
Chief Executive Officer, Executive Director, Since 2013
Salary: Rs123,880,000.00
Bonus: --
Kamal Sharma
Non-Executive Vice Chairman of the Board, Since 2018
Salary: Rs107,290,000.00
Bonus: --
Debabrata Chakravorty
President – Global Sourcing & Contract Manufacturing, Since 2013
Salary: --
Bonus: --
Fabrice Egros
President - Asia Pacific & Japan, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

B/4 Laxmi Towers
, Bandra Kurla Complex, Bandra (
MUMBAI     400051

Phone: +9122.66402222

Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and non-steroidal anti-inflammatory drug therapy areas. The Company also offers solutions in the anti-tuberculosis (anti-TB) and cephalosporins therapy areas. The Company along with its subsidiaries has manufacturing locations spread across India, Japan, the United States, Mexico and Brazil. It has a pipeline of biosimilars addressing therapies, such as oncology, anti-inflammatory, anti-viral, rheumatoid arthritis, endocrinology, diabetes, ophthalmology and women's health. The Company's products include Antara, Methergine, Methylphenidate, Glumetza, Gluconorm, Tonact, Rcinex and Ramistar, among others.

SPONSORED STORIES